pharmaceutical companies manufacturing glp-1 receptor agonist medications GLP Clinical Trial Pipeline Appears Robust With 20+ How GLP-1 medications are transforming
Description
Monnier L, Colette C, Dunseath G, et al
Data were pooled for glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl-peptidase 4 (DPP-4) inhibitors in comparison with their respective controls and expressed as exposure-adjusted incidence rates
Diabetes Metab Syndr Obes, 2020
Lower prices also will be phased in for people without coverage through the administrations TrumpRx program, which will allow people to buy drugs directly from manufacturers
Lancet Diabetes Endocrinol 6(4):275286 Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
doi: 10.1124/pr.115.011395 [DOI] [PMC free article] [PubMed] [Google Scholar] 8
